The deregulated promoter methylation of the Polo-like kinases as a potential biomarker in hematological malignancies

References

• Choi JD, Lee JS. Interplay between epigenetics and genetics in cancer. Genomics Inform 2013;11:164–173.
   PubMedGoogle Scholar
• Hunt KE, Reichard KK. Diffuse large B-cell lymphoma. Arch Pathol Lab Med 2008;132:118–124.
   PubMed Web of Science ®Google Scholar
• Ma X. Epidemiology of myelodysplastic syndromes. Am J Med 2012;125(7 Suppl.):S2–S5.
   PubMed Web of Science ®Google Scholar
• Haase D. Cytogenetic features in myelodysplastic syndromes. Ann Hematol 2008;87:515–526.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937–1947.
   PubMed Web of Science ®Google Scholar
• Issa JP. The myelodysplastic syndrome as a prototypical epigenetic disease. Blood 2013;121:3811–3817.
   PubMed Web of Science ®Google Scholar
• Hayslip J, Montero A. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review. Mol Cancer 2006;5:44.
   PubMed Web of Science ®Google Scholar
• Shaknovich R, Geng H, Johnson NA, et al. DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood 2010;116:e81–e89.
   PubMed Web of Science ®Google Scholar
• Benetatos L, Dasoula A, Hatzimichael E, et al. Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions. Ann Hematol 2011;90:1037–1045.
   PubMed Web of Science ®Google Scholar
• Syed N, Smith P, Sullivan A, et al. Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood. 2006;107:250–256.
   PubMed Web of Science ®Google Scholar
• Pellegrino R, Calvisi DF, Ladu S, et al. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 2010;51:857–868.
   PubMed Web of Science ®Google Scholar
• Ward A, Morettin A, Shum D, et al. Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice. BMC Cancer 2011;11:71.
   PubMed Web of Science ®Google Scholar
• Smith P, Syed N, Crook T. Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3. Cell Cycle 2006;5:1262–1264.
   PubMed Web of Science ®Google Scholar
• Lowery DM, Lim D, Yaffe MB. Structure and function of Polo-like kinases. Oncogene 2005;24:248–259.
   PubMed Web of Science ®Google Scholar
• van de Weerdt BC, Medema RH. Polo-like kinases: a team in control of the division. Cell Cycle 2006;5:853–864.
   PubMed Web of Science ®Google Scholar
• Takai N, Hamanaka R, Yoshimatsu J, et al. Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287–291.
   PubMed Web of Science ®Google Scholar
• Han DP, Zhu QL, Cui JT, et al. Polo-like kinase 1 is overexpressed in colorectal cancer and participates in the migration and invasion of colorectal cancer cells. Med Sci Monit 2012;18:BR237–BR246.
   PubMed Web of Science ®Google Scholar
• Syed N, Coley HM, Sehouli J, et al. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res 2011;71:3317–3327.
   PubMed Web of Science ®Google Scholar
• de Carcer G, Escobar B, Higuero AM, et al. Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol 2011;31:1225–1239.
   PubMed Web of Science ®Google Scholar
• Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821–9826.
   PubMed Web of Science ®Google Scholar
• Renner AG, Dos Santos C, Recher C, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009;114:659–662.
   PubMed Web of Science ®Google Scholar
• Gleixner KV, Ferenc V, Peter B, et al. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI2536. Cancer Res 2010;70: 1513–1523.
   PubMed Web of Science ®Google Scholar
• Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005;24:267–276.
   PubMed Web of Science ®Google Scholar
• Morettin A, Ward A, Nantais J, et al. Gene expression patterns in heterozygous Plk4 murine embryonic fibroblasts. BMC Genomics 2009;10:319.
   PubMed Web of Science ®Google Scholar
• Ko MA, Rosario CO, Hudson JW, et al. Plk4 haploinsufficiency causes mitotic infidelity and carcinogenesis. Nat Genet 2005;37: 883–888.
   PubMed Web of Science ®Google Scholar
• Hudson JW, Kozarova A, Cheung P, et al. Late mitotic failure in mice lacking Sak, a polo-like kinase. Curr Biol 2001;11:441–446.
   PubMed Web of Science ®Google Scholar
• Dementyeva E, Kryukov F, Kubiczkova L, et al. Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma. J Transl Med 2013;11:77.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Ahmann GJ, Henderson K, et al. Clinical implication of centrosome amplification in plasma cell neoplasm. Blood 2006;107:3669–3675.
   PubMed Web of Science ®Google Scholar
• Reuther GW. Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression. Am J Cancer Res 2011;1:752–762.
   PubMed Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 2010;24:1128–1138.
   PubMed Web of Science ®Google Scholar
• Hao Y, Chapuy B, Monti S, et al. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res 2014;20: 2674–2683.
   PubMed Web of Science ®Google Scholar
• James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144–1148.
   PubMed Web of Science ®Google Scholar
• Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007;17:8–14.
   PubMed Web of Science ®Google Scholar
• Liu F, Zhao X, Perna F, et al. JAK2V617F-mediated phosphorylation of PRMT5 downregulates its methyltransferase activity and promotes myeloproliferation. Cancer Cell 2011;19:283–294.
   PubMed Web of Science ®Google Scholar
• Dunphy CH, O’Malley DP, Perkins SL, et al. Analysis of immunohistochemical markers in bone marrow sections to evaluate for myelodysplastic syndromes and acute myeloid leukemias. Appl Immunohistochem Mol Morphol 2007;15:154–159.
   PubMedGoogle Scholar
• Ito S, D’Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010;466:1129–1133.
   PubMed Web of Science ®Google Scholar
• Asmar F, Punj V, Christensen J, et al. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica 2013; 98:1912–1920.
   PubMed Web of Science ®Google Scholar
• Kim Y, Yoon S, Kim SJ, et al. Myeloperoxidase expression in acute myeloid leukemia helps identifying patients to benefit from transplant. Yonsei Med J 2012;53:530–536.
   PubMed Web of Science ®Google Scholar
• Chantrain CF, Feron O, Marbaix E, et al. Bone marrow microenvironment and tumor progression. Cancer Microenviron 2008;1:23–35.
   PubMedGoogle Scholar
• Tirlapur VG, Gicheru K, Charalambous BM, et al. Packed cell volume, haemoglobin, and oxygen saturation changes in healthy smokers and non-smokers. Thorax 1983;38:785–787.
   PubMed Web of Science ®Google Scholar
• Aseervatham GS, Sivasudha T, Jeyadevi R, et al. Environmental factors and unhealthy lifestyle influence oxidative stress in humans–an overview. Environ Sci Pollut Res Int 2013;20: 4356–4369.
   PubMed Web of Science ®Google Scholar
• Kroll ME, Murphy F, Pirie K, et al. Alcohol drinking, tobacco smoking and subtypes of haematological malignancy in the UK Million Women Study. Br J Cancer 2012;107:879–887.
   PubMed Web of Science ®Google Scholar
• Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013;501:328–337.
   PubMed Web of Science ®Google Scholar
• Menzies AM, Haydu LE, Carlino MS, et al. Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma. PLoS One 2014;9:e85004.
   PubMed Web of Science ®Google Scholar
• Yancovitz M, Litterman A, Yoon J, et al. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma. PLoS One 2012;7:e29336.
   PubMed Web of Science ®Google Scholar
• Pike BL, Greiner TC, Wang X, et al. DNA methylation profiles in diffuse large B-cell lymphoma and their relationship to gene expression status. Leukemia 2008;22:1035–1043.
   PubMed Web of Science ®Google Scholar
• Martin-Subero JI, Kreuz M, Bibikova M, et al. New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood 2009;113:2488–2497.
   PubMed Web of Science ®Google Scholar
• Hiraga J, Kinoshita T, Ohno T, et al. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma. Int J Hematol 2006;84:248–255.
   PubMed Web of Science ®Google Scholar
• Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010;17:13–27.
   PubMed Web of Science ®Google Scholar
• Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 2003;109:80–88.
   PubMed Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010;28:605–613.
   PubMed Web of Science ®Google Scholar